Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McClellan evaluates ephedra

This article was originally published in The Tan Sheet

Executive Summary

FDA Commissioner Mark McClellan, MD/PhD, asks RAND Corp.'s Paul Shekelle, MD/PhD, if "the available evidence supports a causal relationship at a somewhat less certain level of scientific proof" than the "95% certainty" standard often used in studies, according to an April 4 email correspondence. Shekelle replies that although "95% certainty" level does not exist to link ephedra with adverse events, "we judge that it is much more likely than not that such a relationship exists" and "we are much more than 50% confident that it exists." McClellan also asks whether evidence of a causal relationship "is more certain for the special circumstances suggested in FDA's proposed warning label," such as strenuous exercise or consumption of other stimulants. Shekelle notes RAND report "did not find sufficient evidence to reach firm conclusions," but adds that does not mean the risk is not increased...

You may also be interested in...

Prop 65 Warnings Intended For Small Spaces But Used On Luggage? California Proposes Limits

California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts